drugset / Trial / NCT00931281

Study in Healthy Adults to Evaluate Pharmacokinetics, Safety and Tolerability of ABT-450 With Ritonavir

NCT00931281

Phase 1 Completed 38 enrolled Abbott
RandomizedParallel-groupDouble-blindTreatment

Summary

The purpose of this study is to evaluate the pharmacokinetics, safety and tolerability of multiple doses of an experimental hepatitis C virus (HCV) protease inhibitor with ritonavir in healthy volunteers.

Timeline

Start
2009-06
Primary completion
2009-09
Completion

Drugs

EvaluationDrugModalityDoseRoute
Comparator paritaprevir Small molecule
Comparator Ritonavir Other / unclassified